Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Diamant Asset Management Inc.

Diamant Asset Management Inc. increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 49.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,700 shares of the company’s stock after acquiring an additional 7,835 shares during the period. Novo Nordisk A/S comprises 1.3% of Diamant Asset Management Inc.’s investment portfolio, making the stock its 18th biggest position. Diamant Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $2,039,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. Mediolanum International Funds Ltd purchased a new position in Novo Nordisk A/S in the 3rd quarter valued at approximately $98,765,000. Wellington Management Group LLP acquired a new position in shares of Novo Nordisk A/S in the third quarter worth $42,017,000. Sanctuary Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the second quarter worth $41,646,000. Finally, World Investment Advisors LLC raised its stake in shares of Novo Nordisk A/S by 2,655.9% in the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after acquiring an additional 270,234 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $87.45 on Tuesday. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market capitalization of $392.43 billion, a PE ratio of 28.30, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a fifty day moving average of $95.35 and a two-hundred day moving average of $114.80.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NVO. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.